Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : DD's DD -- Ignore unavailable to you. Want to Upgrade?

To: Due Diligence who wrote (1449)	11/8/2000 11:43:11 AM
From: Due Diligence	Respond to of 2080

(COMTEX) B: Women First HealthCare Receives $5.5 Million Payment Unde B: Women First HealthCare Receives $5.5 Million Payment Under Recently Revised Ortho-McNeil Pharmaceutical Agreements SAN DIEGO, Nov 8, 2000 /PRNewswire via COMTEX/ -- Women First HealthCare, Inc. (Nasdaq: WFHC) today announced it has received a $5.5 million payment from Ortho-McNeil Pharmaceutical, Inc. The $5.5 million cash receipt represents revenues recorded in the third quarter 2000 under the revised agreements with Ortho-McNeil announced October 17, 2000. "This cash inflow significantly improves our cash position and the stability of our financial condition," said Charles M. Caporale, Women First's vice president and chief financial officer. About Women First HealthCare, Inc. Founded in 1996, Women First HealthCare, Inc. is a San Diego-based company dedicated to improving the health and well being of women transitioning from perimenopause through postmenopause and to supporting the OB/GYNs, Nurse Practitioners, and other health professionals who manage their care. The Company, which has established solutions for midlife women and their clinicians, is structured into three operating divisions. Pharmaceutical is responsible for the marketing of prescription products, which currently include hormone replenishment -- both oral and patch -- and cholesterol- lowering prescription products, and Daily Difference(TM) dietary supplements developed in consultation with Tufts University School of Nutrition Science and Policy. Consumer is responsible for the Company's self-care line of products available through its www.womenfirst.com Marketplace, As We Change(R) national mail order catalog, and Internet retailer, www.aswechange.com. Trialogue(TM), the Corporate Marketing Division, is responsible for providing access to Women First's network of opinion leaders and clinicians through strategic marketing programs for sale to major pharmaceutical companies. Integrated access includes the Company's comprehensive online health portal, www.womenfirst.com/gateway (Professional Gateway for Health Professionals); database communications; and continuing medical education programs. News releases from Women First HealthCare, Inc. are available at no charge on Women First's Web site at www.womenfirst.com and through PR Newswire's On-Call fax service by calling (800) 758-5804, extension 129665. For further information, please contact Charles M. Caporale, Vice President/Chief Financial Officer of Women First HealthCare, Inc., 858-509-3806, ccaporale@womenfirst.com. SOURCE Women First HealthCare, Inc. CONTACT: Charles M. Caporale, Vice President/Chief Financial Officer o Women First HealthCare, Inc., 858-509-3806, ccaporale@womenfi st.com /Company News On-Call: prnewswire.com html or fax, 800-758-5804, ext. 129665 URL: womenfirst.com aswechange.com womenfirst.com prnewswire.com (C) 2000 PR Newswire. All rights reserved. -0- KEYWORD: California INDUSTRY KEYWORD: HEA MTC * end of story *